Talquetamab In Pts With Relapsed Refractory Multiple Myeloma Phase 1 2

Talquetamab In Pts With Relapsed Refractory Multiple Myeloma Phase 1 2 Methods: eligible pts were intolerant to or progressed on established therapies (phase 1) or had ≥3 prior lines of therapy (lot), including ≥1 proteasome inhibitor, ≥1 immunomodulatory drug, and ≥1 anti cd38 antibody (phase 2). pts received rp2ds of sc tal 0.4 mg kg qw or 0.8 mg kg q2w with step up doses. Conclusions: steroid sparing tal dara showed deep and durable responses with promising mpfs in heavily pretreated pts with rrmm, including pts refractory to anti cd38 bcma and t cell redirecting therapy, suggesting combined immunomodulatory actions can yield robust responses in pts with refractory disease. the safety profile was clinically.

Ash 2022 Talquetamab In Patients With Relapsed Refractory Multiple Chari a, touzeau c, schinke c, et al. talquetamab, a g protein coupled receptor family c group 5 member d × cd3 bispecific antibody, in patients with relapsed refractory multiple myeloma: phase 1. Methods: eligible pts for phase 1 of the study had progressed on or could not tolerate established multiple myeloma therapies.in phase 2, eligible pts had been exposed to ≥3 prior lines of therapy including a proteasome inhibitor, an immunomodulatory drug, and an anti cd38 antibody. the current analysis includes all pts across phase 1 and 2. We present updated results of talquetamab at the recommended phase 2 dose (rp2d) from a phase 1 trial in relapsed refractory mm. methods: eligible pts with mm who had relapsed or refractory disease or were intolerant to standard therapies received talquetamab intravenously (iv; range 0.5–180 µg kg) or subcutaneously (sc; range 5.0–800 µg. As of january 17, 2023, supportive phase 1 2 analyses included 20 pts who switched from tal 0.4 mg kg qw to a reduced dose (teae mitigation, n=16; response, n=3; both, n=1), and 6 pts who switched from tal 0.8 mg kg q2w to a reduced dose (teae mitigation, n=4; response, n=2).

Talquetamab Effective In Relapsed Refractory Multiple Myeloma We present updated results of talquetamab at the recommended phase 2 dose (rp2d) from a phase 1 trial in relapsed refractory mm. methods: eligible pts with mm who had relapsed or refractory disease or were intolerant to standard therapies received talquetamab intravenously (iv; range 0.5–180 µg kg) or subcutaneously (sc; range 5.0–800 µg. As of january 17, 2023, supportive phase 1 2 analyses included 20 pts who switched from tal 0.4 mg kg qw to a reduced dose (teae mitigation, n=16; response, n=3; both, n=1), and 6 pts who switched from tal 0.8 mg kg q2w to a reduced dose (teae mitigation, n=4; response, n=2). Study involving patients with relapsed or refrac tory multiple myeloma. methods study design and patients this ongoing, phase 1, open label, multicenter study of talquetamab is composed of a dose. Methods: monumental 2 (nct05050097) is a multi arm, phase 1b study of tal in combination with antimyeloma agents in pts with mm. pts received the recommended phase 2 doses of subcutaneous tal 0.4 mg kg weekly (qw) or 0.8 mg kg every other week (q2w), with step up dosing, oral pom 2 mg daily (dose escalation to 4 mg daily permitted) starting.